PT - JOURNAL ARTICLE AU - Hiam Chemaitelly AU - Houssein H. Ayoub AU - Patrick Tang AU - Peter Coyle AU - Hadi M. Yassine AU - Asmaa A. Al Thani AU - Hebah A. Al-Khatib AU - Mohammad R. Hasan AU - Zaina Al-Kanaani AU - Einas Al-Kuwari AU - Andrew Jeremijenko AU - Anvar Hassan Kaleeckal AU - Ali Nizar Latif AU - Riyazuddin Mohammad Shaik AU - Hanan F. Abdul-Rahim AU - Gheyath K. Nasrallah AU - Mohamed Ghaith Al-Kuwari AU - Adeel A. Butt AU - Hamad Eid Al-Romaihi AU - Mohamed H. Al-Thani AU - Abdullatif Al-Khal AU - Roberto Bertollini AU - Jeremy Samuel Faust AU - Laith J. Abu-Raddad TI - Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting AID - 10.1101/2022.11.14.22282103 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.14.22282103 4099 - http://medrxiv.org/content/early/2022/11/15/2022.11.14.22282103.short 4100 - http://medrxiv.org/content/early/2022/11/15/2022.11.14.22282103.full AB - Background Long-term effectiveness of COVID-19 mRNA boosters in populations with different prior infection histories and clinical vulnerability profiles is inadequately understood.Methods A national, matched, retrospective, target trial cohort study was conducted in Qatar to investigate effectiveness of a third mRNA (booster) dose, relative to a primary series of two doses, against SARS-CoV-2 omicron infection and against severe COVID-19. Associations were estimated using Cox proportional-hazards regression models.Results Booster effectiveness relative to primary series was 41.1% (95% CI: 40.0-42.1%) against infection and 80.5% (95% CI: 55.7-91.4%) against severe, critical, or fatal COVID-19, over one-year follow-up after the booster. Among persons clinically vulnerable to severe COVID-19, effectiveness was 49.7% (95% CI: 47.8-51.6%) against infection and 84.2% (95% CI: 58.8-93.9%) against severe, critical, or fatal COVID-19. Effectiveness against infection was highest at 57.1% (95% CI: 55.9-58.3%) in the first month after the booster but waned thereafter and was modest at only 14.4% (95% CI: 7.3-20.9%) by the sixth month. In the seventh month and thereafter, coincident with BA.4/BA.5 and BA.2.75* subvariant incidence, effectiveness was progressively negative reaching -20.3% (95% CI: -55.0-29.0%) after one year of follow-up. Similar levels and patterns of protection were observed irrespective of prior infection status, clinical vulnerability, or type of vaccine (BNT162b2 versus mRNA-1273).Conclusions Boosters reduced infection and severe COVID-19, particularly among those clinically vulnerable to severe COVID-19. However, protection against infection waned after the booster, and eventually suggested an imprinting effect of compromised protection relative to the primary series. However, imprinting effects are unlikely to negate the overall public health value of booster vaccinations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for institutional salary support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for institutional salary support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review boards at Hamad Medical Corporation and Weill Cornell Medicine in Qatar approved this retrospective study with a waiver of informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted-access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.